However, the bidirectional signalling crosstalk between HER2 and ERα in HER2+/ER+ breast cancer has been reported to contribute to resistance towards both anti-estrogen and HER2-targeted therapies, making efficacious treatment of this group of breast cancer a challenge [6, 8]. This evidence concerns the gene ERBB2 and breast carcinoma.